DOCSLIB.ORG

Lydia Normal.Dot

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Lydia Normal.Dot Comprehensive Summaries of Uppsala Dissertations from the Faculty of Pharmacy 256 _____________________________ _____________________________ Clinical-Pharmacokinetic Aspects of Prolonged Effect Duration as Illustrated by β2-Agonists BY JOHAN ROSENBORG ACTA UNIVERSITATIS UPSALIENSIS UPPSALA 2001 Dissertation for the Degree of Doctor of Philosophy (Faculty of Pharmacy) Pharmacokinetics and Drug Therapy presented at Uppsala in 2001 ABSTRACT Rosenborg, J. 2001. Clinical-Pharmacokinetic Aspects of Prolonged Effect Duration as Illustrated by β2-Agonists. Acta Univ. Ups. Comprehensive Summaries of Uppsala Dissertations from the Faculty of Pharmacy 256. 41 pp. Uppsala. ISBN 91-554-5099-7. Regularity is a key element of maintenance drug treatment; compliance is crucial for treatment success. Once- or twice-daily intake of a drug is always easier to comply with than regimens requiring more frequent dosing. Bronchodilating treatment was used as an example to illustrate how sustained duration of effect can be achieved by two different approaches: oral administration of the terbutaline prodrug bambuterol and inhalation of formoterol. Bioanalytical methods were employed to monitor the kinetic fate of bambuterol and formoterol in plasma, urine, or faeces. Generated terbutaline in plasma was used as a marker of effect for bambuterol. Established clinical laboratory tests were used to assess local and systemic effects of inhaled formoterol compared with salbutamol. Recommended doses of bambuterol, 10-20 mg once daily in adults, normally produced plasma concentrations of the active moiety terbutaline within therapeutically relevant limits. Dose proportionality for terbutaline makes dosing with bambuterol predictable. Compared with adults, children should be given higher doses than indicated by their lower body weight. Pharmacokinetic analysis indicated that absorption of bambuterol was slow and multi-phasic and that slow biotransformation to terbutaline occurred both presystemically and systemically. Systemically circulating formoterol was rapidly eliminated, the inactive (S;S)-formoterol more rapidly than the active (R;R)-formoterol. An inactive phenol glucuronide was the main metabolite, and a previously unknown sulphate metabolite was discovered. Duration of systemically mediated cardiovascular or metabolic side-effects of inhaled formoterol seemed not to differ from those of an inhaled systemically equieffective dose of salbutamol. There was a trend suggesting that the magnitude of systemic side-effects may be less pronounced after inhalation of formoterol compared with a locally equieffective dose of inhaled salbutamol. Both approaches to sustaining stimulation of β2-adrenoceptors have their pros and cons. Bambuterol can be dosed orally once daily, but full effect is reached slowly. The effect of formoterol is reached within a few minutes, but administration must occur via the lungs, often twice daily. Both treatments, however, give 24-h symptom relief during regular treatment. Johan Rosenborg, Department of Pharmaceutical Biosciences, Division of Pharmacokinetics and Drug Therapy, BMC, Box 591, SE-751 24 Uppsala, Sweden and Experimental Medicine, AstraZeneca R&D Lund, SE-221 87 Lund, Sweden Johan Rosenborg 2001 ISSN 0282-7484 ISBN 91-554-5099-7 Printed in Sweden by Lindbergs Grafiska HB, Uppsala 2001 PAPERS DISCUSSED This thesis is based on the following papers, which will be referred to in the text by their Roman numerals. I. Rosenborg J, Larsson P, Nyberg L. Pharmacokinetics of bambuterol during oral administration of plain tablets and solution to healthy adults. Br J Clin Pharmacol 2000;49:199-206. II. Ahlström H, Alvero J, Alvero R, et al. Pharmacokinetics of bambuterol during oral administration to asthmatic children. Br J Clin Pharmacol 1999;48:299-308. III. Rosenborg J, Larsson P, Tegnér K, Hallström G. Mass balance and metabolism of 3H-formoterol in healthy men after combined i.v. and oral administration - mimicking inhalation. Drug Metab Dispos 1999;27:1104-1116. IV. Rosenborg J, Bengtsson T, Larsson P, Blomgren A, Persson G, Lötvall J. Relative systemic dose potency and tolerability of inhaled formoterol and salbutamol in healthy subjects and asthmatics. Eur J Clin Pharmacol 2000;56:363-370. V. Rosenborg J, Larsson P, Rott Z, Böcskei C, Poczi M, Juhász G. Assessment of a relative therapeutic index between inhaled formoterol and salbutamol in asthma patients. Submitted 2001. ABBREVIATIONS USED IN FRAME STORY Ae Amount excreted in urine during a collection interval ANOVA Analysis of variance AUC Area under the curve of plasma concentration vs time CLA Apparent clearance after oral administration (dependent also on bioavailability) CLR Renal clearance ESI Electrospray ionization FEV1 Forced expiratory volume (L) in the first second 3 H2O Tritiated water F Formoterol FG1 Phenol glucuronide of formoterol FG2 Benzyl glucuronide of formoterol FS Sulphate of formoterol S-K+ Serum concentration of the potassium ion LC Liquid chromatography LOQ Limit of quantification Met1 O-demethylated formoterol Met1G1 Phenol glucuronide 1 of O-demethylated formoterol Met1G2 Phenol glucuronide 2 of O-demethylated formoterol Met2S Sulphate of deformylated formoterol MS Mass spectrometry Q-Tc Q-T interval corrected for heart rate (R;R)/(S;S) Ratio of formoterol enantiomers in urine T½ Terminal half-life Total Total radioactivity: the sum of formoterol plus metabolites and tritiated water excreted in urine and faeces XTOT Quantified unidentified metabolites of formoterol CONTENTS INTRODUCTION......................................................................................................................................7 BASIC PHARMACOLOGY OF β2-AGONISTS....................................................................................7 STRUCTURE, ACTIVITY, AND SELECTIVITY ...............................................................................................7 PULMONARY PHARMACOLOGY .................................................................................................................9 EXTRAPULMONARY PHARMACOLOGY ......................................................................................................9 METABOLIC EFFECTS..............................................................................................................................10 THE RELATION BETWEEN PHARMACOKINETICS AND PHARMACODYNAMICS ...........................................10 PHARMACOKINETIC QUALITIES OF LONG-ACTING β2-AGONISTS..............................................................10 PROLONGED DURATION OF BRONCHODILATION – PREVIOUS RESULTS........................12 PROLONGED SYSTEMICALLY-MEDIATED EFFECT OF THE SHORT-ACTING β2-AGONIST TERBUTALINE USING PRODRUGS ..............................................................................................................................................12 PHARMACOKINETIC BASIS OF PROLONGED TOPICALLY-MEDIATED EFFECT .............................................15 PRESENT INVESTIGATION................................................................................................................17 OBJECTIVES............................................................................................................................................17 METHODS ...............................................................................................................................................17 Pharmacokinetics of bambuterol......................................................................................................17 Fitting a pharmacokinetic model to previous data on bambuterol................................................................ 17 Study designs ............................................................................................................................................... 18 Bioanalysis................................................................................................................................................... 19 Calculations and primary statistical analyses............................................................................................... 20 Pharmacokinetics and effects of formoterol .....................................................................................21 Study designs ............................................................................................................................................... 21 Effect measurements and bioanalysis........................................................................................................... 22 Calculations and primary statistical analyses............................................................................................... 23 RESULTS.................................................................................................................................................24 Pharmacokinetic modelling of previous data on bambuterol...........................................................24 Pharmacokinetics of bambuterol tablets and solution (Papers I and II)..........................................25 Mass balance and metabolism of 3H-formoterol in healthy men (Paper III) ...................................28 Relative systemic dose potency and tolerability of inhaled formoterol and salbutamol in healthy subjects and asthmatics (Paper IV) ..................................................................................................29 Assessment of a relative therapeutic index between inhaled formoterol and salbutamol
Load more

Recommended publications
  • Dosing Time Matters
    bioRxiv preprint doi: https://doi.org/10.1101/570119; this version posted March 21, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Dosing Time Matters 1 2,3 4,5,6 1* Marc D. Ruben ,​ David F. Smith ,​ Garret A. FitzGerald ,​ and John B. Hogenesch ​ ​ ​ ​ 1 Division​ of Human Genetics, Center for Chronobiology, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, 240 Albert Sabin Way, Cincinnati, OH, 45229 2 Divisions​ of Pediatric Otolaryngology and Pulmonary and Sleep Medicine, Cincinnati Children’s Hospital Medical Center, 3333 Burnet Ave, Cincinnati, OH 45229 3 Department​ of Otolaryngology-Head and Neck Surgery, University of Cincinnati School of Medicine, 231 Albert Sabin Way, Cincinnati, OH, 45267 4 Department​ of Systems Pharmacology and Translational Therapeutics, at the University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104 USA 5 Department​ of Medicine, at the University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104 USA 6 ​ Institute for Translational Medicine and Therapeutics (ITMAT), at the University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104 USA *Corresponding Author. Email: [email protected] Abstract Trainees in medicine are taught to diagnose and administer treatment as needed; time-of-day is rarely considered. Yet accumulating evidence shows that ~half of human genes and physiologic functions follow daily rhythms. Circadian medicine aims to incorporate knowledge of these rhythms to enhance diagnosis and treatment.
    [Show full text]
  • 1 Effect of Indacaterol, a Novel Long-Acting Beta 2
    ERJ Express. Published on November 29, 2006 as doi: 10.1183/09031936.00032806 EFFECT OF INDACATEROL, A NOVEL LONG-ACTING BETA 2-AGONIST, ON HUMAN ISOLATED BRONCHI Emmanuel Naline (1), Alexandre Trifilieff (2), Robin A. Fairhurst (2), Charles Advenier (1), Mathieu Molimard (3) (1) Research Unit EA220, Université de Versailles, Faculté de Médecine, Pharmacology, Hôpital Foch, 40 rue Worth, 92150 Suresnes, France (2) Novartis Institute for BioMedical Research, Horsham, England (3) Département de Pharmacologie, Université Victor Segalen Bordeaux 2; CHU Pellegrin; INSERM U657, Bordeaux, France Correspondence: Mathieu Molimard Département de Pharmacologie CHU de Bordeaux - Université Victor Segalen-INSERM U657 33076 Bordeaux cedex, France Phone: 33 (0)5 57 57 15 60 Fax: 33 (0)5 57 57 46 71 E-mail: [email protected] Short title: Indacaterol effect on isolated human bronchi 1 Copyright 2006 by the European Respiratory Society. Abstract Indacaterol is a novel β2-adrenoceptor agonist in development for the once-daily treatment of asthma and COPD. This study evaluated the relaxant effect of indacaterol on isolated human bronchi obtained from lungs of patients undergoing surgery for lung carcinoma. Potency (-logEC50), intrinsic efficacy (Emax) and onset of action were determined at resting tone. Duration of action was determined against cholinergic neural contraction induced by electrical field stimulation (EFS). At resting tone, -logEC50 and Emax values were, respectively, 8.82±0.41 and 77±5% for indacaterol, 9.84±0.22 and 94±1% for formoterol, 8.36±0.16 and 74±4% for salmeterol, and 8.43±0.22 and 84±4% for salbutamol. In contrast to salmeterol, indacaterol did not antagonize the isoprenaline response.
    [Show full text]
  • Onset of Action of Relaxants Francois Donati PH D MD FRCPC
    $52 REFRESHER COURSE OUTLINE Onset of action of relaxants Francois Donati PH D MD FRCPC Induction of anaesthesia must be performed carefully Cardiac outFur with special attention to the possibility of hypoxia and After intravenous injection, the drug is carried to the aspiration of gastric contents. These problems are largely central circulation where it ruixes with venous blood avoided by the proper placement of a tracheal tube and coming from all organs. Then it enters the ride side of the mechanical ventilation. However, the degree of paralysis heart, goes through the pulmonary circulation and the left required for easy laryngoscopy and tracheal intubation is side of the heart to the aorta. The transition time from not achieved immediately after the injection of the peripheral venous to arterial circulation depends on relaxant drug. The time delay between inducing anaesthe- cardiac output. Not surprisingly, cardiac output has been sia and securing the airway should be considered a danger identified as a major factor affecting succinylcholine period which should be shortened as much as possible. onset time. 13 The onset time of non-depolarizing relax- For the past 35 years, succinylcholine has been the drug ants was found to be shorter in infants, who have a of choice to achieve profound neuromuscular blockade relatively large cardiac output, than in older children. 14' 15 rapidly. Doses of 1- 1.5 mg. kg- i provide excellent intu- Within the adult population, the onset of pancuronium bat[ne conditions in 60 to 90 seconds 1-7 Unfortunately,
    [Show full text]
  • Trimbow, INN-Beclometasone / Formoterol / Glycopyrronium Bromide
    23 May 2017 EMA/CHMP/290028/2017 – Rev 1 Committee for Medicinal Products for Human Use (CHMP) Summary of opinion1 (initial authorisation) Trimbow beclometasone / formoterol / glycopyrronium bromide On 18 May 2017, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Trimbow, intended for the maintenance treatment of moderate to severe chronic obstructive pulmonary disease (COPD). The applicant for this medicinal product is Chiesi Farmaceutici S.p.A., Italy. Trimbow is a triple combination of an inhaled glucocorticoid (beclometasone dipropionate), a long-acting beta2 receptor agonist (formoterol fumarate dihydrate) and a long-acting muscarinic antagonist (glycopyrronium bromide). It will be available as a pressurised metered dose inhaler delivering a solution with a nominal dose per actuation of 87 micrograms / 5 micrograms / 9 micrograms of the active substances respectively. Beclometasone reduces inflammation in the lungs, whereas formoterol and glycopyrronium produce relaxation of bronchial smooth muscle helping to dilate the airways and make breathing easier (ATC code: R03AL09). The benefits with Trimbow are its ability to relieve and prevent symptoms such as shortness of breath, wheezing and cough and to reduce exacerbations of COPD symptoms. The most common side effects of Trimbow are oral candidiasis, muscle spasm and dry mouth. The full indication is: “Maintenance treatment in adult patients with moderate to severe
    [Show full text]
  • 22518Orig1s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 22518Orig1s000 CLINICAL PHARMACOLOGY AND BIOPHARMACEUTICS REVIEW(S) 7 CLINICAL PHARMACOLOGY REVIEW NDA: 22-518 Brand Name: Dulera Generic Name: Mometosone furoate / formoterol fumarate Indication: Asthma (b) (4) in adults and children 12 years of age and older Dosage Form: Inhalation aerosol Strengths: (b) (4) 100/5, 200/5 mcg Route of Administration: Oral Inhalation Dosing regimen: Two inhalations twice daily (morning and evening) Applicant: Schering-Plough and Novartis OCP Division: DCP2 Clinical Division: DPAP (OND-570) Submission Date: May 21, 2009 Reviewers: Ying Fan, Ph.D., Liang Zhao, Ph.D. Team Leader (Acting): Partha Roy, Ph. D. TABLE OF CONTENTS 1 EXECUTIVE SUMMARY.................................................................................................... 3 1.1 Recommendations ........................................................................................................................3 1.2 Phase IV commitments.................................................................................................................3 1.3 Summary of Clinical Pharmacology and Biopharmaceutics findings.....................................3 2 QUESTION BASED REVIEW............................................................................................. 9 2.1 General Attributes/Background..................................................................................................9 2.1.1 What is the pertinent regulatory background of DULERA? .....................................
    [Show full text]
  • Bioavailability and Bioeqivalence
    UNIT 5 BIOAVAILABILITY AND BIOEQIVALENCE S. SANGEETHA., M.PHARM., (Ph.d) Department of Pharmaceutics SRM College of Pharmacy SRM University BIOAVAILABILITY INTRODUCTION ¾The bioavailability or systemic availability of an orally administered drug depends largely on the absorption and the extent of hepatic metabolism ¾The bioavailability of an oral dosage form is determined by comparing the Area Under Curve (AUC) after oral administration of a single dose with that obtained when given IV Drug bioavailability = AUC (oral) AUC (IV) = Bioavailable dose Administered dose DEFINITION Bioavailability is defined as the rate and the absorption of drug that reaches the biological system in an active form, capable of exerting the desired pharmacological effect, including its onset, intensity and duration of its action. THE NEED FOR BIOAVAILABILITY STUDIES ¾Bioavailability studies provide and estimate of the fraction of the orally administered dose that is absorbed into the systemic circulation when compared to the bioavailability for a solution, suspension, or intravenous dosage form that is completely available. ¾Bioavailability studies provide other useful information that is important to establish dosage regimen and to support drug labeling, such as distribution and elimination characteristics of the drug ¾Bioavailability studies provide information regarding the performance of the formulation TYPES OF BIOAVAILABILITY Absolute bioavailability – Absolute bioavailability of a drug in a formulation administered by an extravascular, including the oral route reaching the systemic circulation is the fraction of the same dose of the drug administered intravenously. Absolute bioavailability= (AUC) abs (AUC) iv Absolute bioavailability = (AUC) abs x Div (AUC) iv x Dabs Where Dabs is the size of the single dose administered via the absorption site And Div is the dose size administered intravenously.
    [Show full text]
  • Beclometasone / Formoterol / Glycopyrronium Bromide Pressurised Metered Dose Inhaler (Trimbow®) for the Treatment of COPD
    Beclometasone / formoterol / glycopyrronium bromide pressurised metered dose inhaler (Trimbow®) for the treatment of COPD Commissioning Statement Fylde and Wyre Clinical Commissioning Group has agreed to fund the prescribing of Beclometasone / formoterol / glycopyrronium bromide pressurised metered dose inhaler (Trimbow®) for the treatment of COPD Restriction: Triple therapy should be reserved for patients who have failed to achieve or maintain an adequate response to an appropriate course of dual therapy This medicine is classified as GREEN (Restricted) for this indication Summary of supporting evidence TRILOGY shows that in patients with COPD who have severe or very severe airflow limitation,symptoms, and an exacerbation history, triple therapy with BDP/FF/GB (beclomethasone dipropionate / formoterol fumarate / glycopyrronium bromide) had a greater effect on pre-dose and 2-h post-dose FEV1 than BDP/FF. For the co-primary endpoint measuring breathlessness (Transition Dyspnea Index, TDI), superiority of BDP/FF/GB over BDP/FF was not shown. The rate of moderate-to-severe COPD exacerbations was 23% lower with BDP/FF/GB compared with BDP/FF, with the time to first exacerbation significantly longer with triple therapy. Thus, the greater improvement in lung function with BDP/FF/GB compared with BDP/FF was more clearly accompanied by a reduction in exacerbations than an improvement in breathlessness in this group of patients. Furthermore, BDP/FF/GB had a greater effect on health related quality of life than BDP/FF. TRINITY met the primary and both key secondary endpoints. Extrafine fixed triple (i.e. extra fine inhaled particle fraction, ICS/LABA/LAMA in one inhaler) resulted in a 20% (95% CI 8– 31) reduction in the rate of moderate-to-severe COPD exacerbations compared with tiotropium, together with a 0·061L mean improvement in pre-dose FEV1.
    [Show full text]
  • CBCS SYLLABUS) SUBJECT-BPH C 801 T-Pharmaceutical Chemistry III MULTIPLE CHOICE QUESTIONS: PRACTICE QUESTION BANK
    FINAL YEAR UNIVERSITY EXAMINATION 2019-2020 Final Year B.Pharm. Semester VIII (CBCS SYLLABUS) SUBJECT-BPH_C_801_T-Pharmaceutical Chemistry III MULTIPLE CHOICE QUESTIONS: PRACTICE QUESTION BANK SET-I Q. 1 Which is the correct IUPAC name for the following structure? A] 5-chloro-2-(methylamino)-5-phenyl-3H-1,4-benzodiazepine B] 7-chloro-2-(methylamino)-5-pyridinyl-3H-1,4-benzodiazepine-4-oxide C] 7-chloro-2-(ethylamino)-5-phenyl-3H-1,5-benzodiazepine D] 7-chloro-2-(methylamino)-5-phenyl-3H-1,4-benzodiazepine-4-oxide Q. 2 Which of the following is long acting sedative hypnotic? A] Diazepam B] Alprazolam C] Temazepam D] Imipramine Q. 3 Name of oxide derivative used as sedative hypnotic is A] Diazepam B] Chlordiazepoxide C]Nitazepam D] Ramelteon Q. 4 With respect to the following general structure which is the correctstatement ? A] X must be electropositive substituent for optimum activity B] X must be aromatic ring for optimum activity C] X must be electronegative substituent for optimum activity D] X must be H for optimum activity Q. 5 Which is the incorrect statement with respect to structure given in Q. 4 A] Ring C is ortho substituted with electron withdrawing group for optimum activity B] Ring C when para substituted increases activity C] Ring C is diortho substituted with electron withdrawing group for optimum activity D] Ring C when para substituted decreases activity Q. 6 What is the starting material for synthesis of Piroxicam (structure given below) A] B] C] D] Q. 7 Which one of the following is Cytokine inhibitor? A] Abatacept B] Fluoxetine C] Propranolol D]Aldosterone Q.
    [Show full text]
  • COVID-19 Evidence Bulletin 8
    COVID-19 Evidence Bulletin 8 Public Health England PHE International Epidemiology Daily Evidence Digest – 22nd April 2020 – 21st April 2020 – 20th April 2020 NICE COVID-19 rapid guideline: acute myocardial injury [NG171] Published 23rd April The purpose of this guideline is to help healthcare professionals who are not cardiology specialists identify and treat acute myocardial injury and its cardiac complications in adults with known or suspected COVID-19 but without known pre-existing cardiovascular disease. COVID-19 rapid guideline: gastrointestinal and liver conditions treated with drugs affecting the immune response [NG172] Published 23rd April The purpose of this guideline is to maximise the safety of children and adults who have gastrointestinal or liver conditions treated with drugs affecting the immune response during the COVID 19 pandemic. It also aims to protect staff from infection and enable services to make the best use of NHS resources. COVID-19 rapid guideline: managing symptoms (including at the end of life) in the community Published 3rd April, Last updated 22nd April NHS England Specialty Guides: Clinical guide for acute kidney injury in hospitalised patients with COVID-19 outside the intensive care unit during the coronavirus pandemic (22nd April - updated) Management of palliative care in hospital during the coronavirus pandemic (22nd April – updated) Department of Health and Social Care Medicines that cannot be parallel exported from the UK (22nd April) 33 medicines have been added to the parallel export list and the
    [Show full text]
  • Diagnosis and Management of Asthma in Older Adults Sanjay Haresh Chotirmall, MD, Michael Watts, MD, Peter Branagan, MD, Ciaran F
    PROGRESS IN GERIATRICS Diagnosis and Management of Asthma in Older Adults Sanjay Haresh Chotirmall, MD, Michael Watts, MD, Peter Branagan, MD, Ciaran F. Donegan, MD, Allan Moore, MD, and Noel Gerard McElvaney, MD Despite comprehensive guidelines established by the Euro- from 6.5% to 17.0%.5 Death rates associated with asthma pean Global Initiative for Asthma and the U.S. National depend on patient age; in a group of patients aged 55 to 59, Asthma Education and Prevention Program on the diagno- the death rate was 2.8 per 100,000 people, whereas in sis and management of asthma, its mortality in older adults people aged 60 to 64, it was 4.2 per 100, 000.6 Diagnostic continues to rise. Diagnostic and therapeutic problems and therapeutic problems contribute to many patients being contribute to older patients being inadequately treated. The inadequately treated. Despite its importance in older pa- diagnosis of asthma rests on the history and characteristic tients, asthma is particularly difficult to diagnose in this age pulmonary function testing (PFT) with the demonstration group. Symptoms typical of asthma such as intermittent of reversible airway obstruction, but there are unique prob- wheezing, breathlessness, and cough can also indicate other lems in performing this test in older patients and in its in- respiratory problems in older patients, particularly chronic terpretation. This review aims to address the difficulties in obstructive pulmonary disease (COPD). Similarly, other performing and interpreting PFT in older patients because symptoms of asthma such as chest pain or tightness may of the effects of age-related changes in lung function on be due to nonpulmonary disease such as ischemic heart respiratory physiology.
    [Show full text]
  • Application Number
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 203975s000 SUMMARY REVIEW SUMMARY REVIEW OF REGULATORY ACTION Date: November 26, 2013 From: Badrul A. Chowdhury, MD, PhD Director, Division of Pulmonary, Allergy, and Rheumatology Products, CDER, FDA Subject: Division Director Summary Review NDA Number: 20-3975 Applicant Name: GlaxoSmithKline Date of Submission: December 18, 2012 PDUFA Goal Date: December 18, 2013 Proprietary Name: Anoro Ellipta Established Name: Umeclidinium and vilanterol Dosage form: Inhalation Powder (inhaler contains 2 double-foil blister strips, each with 30 blisters containing powder for oral inhalation) Strength: Umeclidinium 62.5 mcg per blister and vilanterol 25 mcg per blister Proposed Indications: Maintenance treatment of airflow obstruction in chronic obstructive pulmonary disease (COPD) Action: Approval 1. Introduction GlaxoSmithKline (GSK) submitted this 505(b)(1) new drug application for use of Anoro Ellipta (umeclidinium 62.5 mcg and vilanterol 25 mcg inhalation powder) for long-term once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD). The proposed dose is one inhalation (umeclidinium 62.5 mcg and vilanterol 25 mcg) once daily. The application is based on clinical efficacy and safety studies. This summary review will provide an overview of the application, with a focus on the clinical efficacy and safety studies. 2. Background There are several drug classes available for the relief of airflow obstruction in patients with COPD. These include short- and long-acting beta-2 adrenergic agonists, short- and long-acting anticholinergics, combination products containing beta-2 adrenergic agonists and anticholinergics, combination of long-acting beta-2 adrenergic agonists and corticosteroids, methylxanthines, and phosphodiesterase-4 (PDE4) inhibitors.
    [Show full text]
  • Pharmacology Part 2: Introduction to Pharmacokinetics
    J of Nuclear Medicine Technology, first published online May 3, 2018 as doi:10.2967/jnmt.117.199638 PHARMACOLOGY PART 2: INTRODUCTION TO PHARMACOKINETICS. Geoffrey M Currie Faculty of Science, Charles Sturt University, Wagga Wagga, Australia. Regis University, Boston, USA. Correspondence: Geoff Currie Faculty of Science Locked Bag 588 Charles Sturt University Wagga Wagga 2678 Australia Telephone: 02 69332822 Facsimile: 02 69332588 Email: [email protected] Foot line: Introduction to Pharmacokinetics 1 Abstract Pharmacology principles provide key understanding that underpins the clinical and research roles of nuclear medicine practitioners. This article is the second in a series of articles that aims to enhance the understanding of pharmacological principles relevant to nuclear medicine. This article will build on the introductory concepts, terminology and principles of pharmacodynamics explored in the first article in the series. Specifically, this article will focus on the basic principles associated with pharmacokinetics. Article 3 will outline pharmacology relevant to pharmaceutical interventions and adjunctive medications employed in general nuclear medicine, the fourth pharmacology relevant to pharmaceutical interventions and adjunctive medications employed in nuclear cardiology, the fifth the pharmacology related to contrast media associated with computed tomography (CT) and magnetic resonance imaging (MRI), and the final article will address drugs in the emergency trolley. 2 Introduction As previously outlined (1), pharmacology is the scientific study of the action and effects of drugs on living systems and the interaction of drugs with living systems (1-7). For general purposes, pharmacology is divided into pharmacodynamics and pharmacokinetics (Figure 1). The principle of pharmacokinetics is captured by philosophy of Paracelsus (medieval alchemist); “only the dose makes a thing not a poison” (1,8,9).
    [Show full text]